Company intelligence / Profile preview

United Lee

Hefei, Anhui, China

Ownership: Private
Development stage: Other

Overview

Multiple products approved and launched in China, including Socazolimab Injection (PDL1 inhibitor for oncology), Adapalene and Clindamycin Hydrochloride Gel for acne, and others in cardiovascular and rare diseases; over 40 products in pipeline from early to late-stage.

Therapeutic areas: Women's HealthCardiovascularDermatologyInfectious DiseasesRare DiseasesOncologyOphthalmology
Modalities: Small moleculeBiological productsMonoclonal antibody
Industry: Biotech

Partnerships

United Therapeutics (Remodulin distribution)Shaohe Biotechnology (probiotics)Around 30 international companies

Beyond the preview

Go deeper on United Lee.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on United Lee.

Explore the full profile